Wagmann, L, Richter, LHJ, Kehl, T, Wack, F, Pettersson Bergstrand, M, Brandt, SD, Stratford, A, Maurer, HH and Meyer, MR

In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures

Analytical and Bioanalytical Chemistry

Electronic Supplementary Material

In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures

Lea Wagmann, Lilian H. J. Richter, Tobias Kehl, Franziska Wack, Madeleine Pettersson Bergstrand, Simon D. Brandt, Alexander Stratford, Hans H. Maurer, and Markus R. Meyer









Fig. S1: HRMS/MS spectra of LSD-based new psychoactive substances and their most abundant, unique metabolites along with their retention times (RT). Numbering according to Table 1 in the manuscript.









Fig. S1 (continued)



23 AL-LAD, RT 6.2 min



26 *N*-Deethyl AL-LAD, RT 4.2 min



34 ECPLA, RT 6.0 min



41 Hydroxy ECPLA isomer 3, RT 4.2 min

Fig. S1 (continued)



43 LSZ, RT 5.3 min



47 Hydroxy LSZ isomer 2, RT 3.9 min



51 LSM-775, RT 3.5 min



53 Hydroxy LSM-775 isomer 1, RT 1.5 min

Fig. S1 (continued)



Fig. S2: Metabolic pathways of LSD studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.



Fig. S3: Metabolic pathways of ALD-52 studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.



Fig. S4: Metabolic pathways of 1B-LSD studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.



Fig. S5: Metabolic pathways of ETH-LAD studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.



Fig. S6: Metabolic pathways of 1P-ETH-LAD studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.



Fig. S7: Metabolic pathways of AL-LAD studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.



Fig. S8: Metabolic pathways of ECPLA studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.



Fig. S9: Metabolic pathways of LSZ studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.



Fig. S10: Metabolic pathways of LSM-775 studied in incubations with pooled human liver S9 fraction. Numbering according to Table 1 in the manuscript.